FDA Grants Orphan Drug Status to Akeso’s Ligufalimab for AML
Akeso Inc. announced that its monoclonal antibody ligufalimab (AK117), targeting CD47, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration for the…
Read More...
Read More...
